Exhibit 99.2

Harnessing the Power of Proteomics LEADING AI - DATA DRIVEN PROTEIN PLATFORM Global commercial and technological leader for bio - pharma and clinical protein discovery, measurement and interpretation MARCH 2021

Disclaimer This confidential presentation (the “presentation”) is being delivered to you by CM Life Sciences II, Inc. (“CM Life Sciences II ”) and Somalogic , Inc. (“ Somalogic ”) for use by Somalogic and CM Life Sciences II in connection with their proposed business combination and the offering of the securities of CM Life Sciences II in a private placement (th e “ Transaction”). This presentation is for information purposes only and is being provided to you solely in your capacity as a potential investor in considering an investment in CM Life Sciences II. Any reproduction or dist rib ution of this presentation, in whole or in part, or the disclosure of its contents, without the prior consent of CM Life Sciences II or Somalogic is prohibited. By accepting this presentation, each recipient and its directors, partners, officers, employees, attorney(s), ag ents and representatives (“recipient”) agrees: ( i ) to maintain the confidentiality of all information that is contained in this presentation and not already in the public domain; and (ii) to return or destroy all copies of this presentation or portions thereof in its possession following the request for the return or destruction of such copies. This presentation and any oral statements made in connection with this presentation shall neither constitute an offer to sell no r the solicitation of an offer to buy any securities, or the solicitation of any proxy, vote, consent or approval in any jurisdiction in connection with the proposed business combination, nor shall there be any sale of securities in any jurisdiction in which the offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdictions. This communication is restricted by law; it is not intende d f or distribution to, or use by any person in, any jurisdiction where such distribution or use would be contrary to local law or regulation. No Representations and Warranties This presentation is for informational purposes only and does not purport to contain all of the information that may be requi red to evaluate a possible investment decision with respect to CM Life Sciences II. The recipient agrees and acknowledges that this presentation is not intended to form the basis of any investment decision by the recipient and does not constitute investment, tax or legal advice. No representation or warranty, express or implied, is or will be given by CM Life Sciences II or Somalogic or any of their respective affiliates, directors, officers, employees or advisers or any other person as to the accuracy or c om pleteness of the information in this presentation or any other written, oral or other communications transmitted or otherwise made available to any party in the c our se of its evaluation of a possible transaction between CM Life Sciences II and Somalogic and no responsibility or liability whatsoever is accepted for the accuracy or sufficiency thereof or for any errors, omissions or mi sstatements, negligent or otherwise, relating thereto. The recipient also acknowledges and agrees that the information contained in this presentation is preliminary in nature and is subject to change, and any such changes m ay be material. CM Life Sciences II and Somalogic disclaim any duty to update the information contained in this presentation. Forward - Looking Statements This presentation includes “forward - looking statements” within the meaning of the “safe harbor” provisions of the Private Securi ties Litigation Reform Act of 1996. CM Life Sciences II’s and Somalogic’s actual results may differ from their expectations, estimates and projections and consequently, you should not rely on these forward - looking stateme nts as predictions of future events. Words such as “expect”, “estimate”, “project”, “budget”, “forecast”, “anticipate”, “intend”, “plan”, “may”, “will”, “could”, “should”, “believes”, “predicts”, “potential”, “continue” , a nd similar expressions are intended to identify such forward - looking statements. These forward - looking statements include, without limitation, CM Life Sciences II’s and Somalogic’s expectations with respect to future performance and anticipated financial impacts of the Transaction, the satisfaction of clo si ng conditions to the Transaction and the timing of the completion of the Transaction. These forward - looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. You should carefully consider the risks and uncertainties described in the “Risk Factors” section of CM Life Sciences II’s re gis tration statement on Form S - 1. In addition, there will be risks and uncertainties described in the registration statement on Form S - 4, including the proxy statement/prospectus, relating to the business combination, which is exp ected to be filed by CM Life Sciences II with the Securities and Exchange Commission (the “SEC”) and other documents filed by CM Life Sciences II from time to time with the SEC. These filings identify and address ot her important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward looking statements. Most of these factors are outside CM Life Sciences II’s an d Somalogic’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the outcome of any legal proceedings that may be instituted against CM Life Sciences II or Somalogic following the announcement of the Transaction; (2) the inability to complete the Transaction, including due to the inability to concurrently close the business combination and the private placement of common stock or du e t o failure to obtain approval of the stockholders of CM Life Sciences II; (3) delays in obtaining, adverse conditions contained in, or the inability to obtain any necessary regulatory approvals or complete regular reviews re qui red to complete the Transaction; (4) the risk that the Transaction disrupts current plans and operations as a result of the announcement and consummation of the Transaction; (5) the inability to recognize the anticipate d b enefits of the Transaction, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably, maintain relationships with customers and suppliers and re tain its key employees; (6) costs related to the Transaction; (7) changes in the applicable laws or regulations; (8) the possibility that the combined company may be adversely affected by other economic, business, and /or competitive factors; (9) the impact of the global COVID - 19 pandemic; and (10) other risks and uncertainties indicated from time to time described in CM Life Sciences II’s registration on Form S - 1, including those under “Risk Factors” therein, and in CM Life Sciences II’s other filings with the SEC. CM Life Sciences II and Somalogic caution that the foregoing list of factors is not exclusive and not to place undue reliance upon any forward - looking statements , including projections, which speak only as of the date made. Neither CM Life Sciences II nor Somalogic undertakes or accepts any obligation to release publicly any updates or revisions to any forward - looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based. ® 2021 SOMALOGIC, INC. ALL RIGHTS RESERVED. PROPRIETARY AND CONFIDENTIAL.

Disclaimer Industry and Market Data In this presentation, CM Life Sciences II and Somalogic rely on and refer to publicly available information and statistics regarding market participants in the sectors in which Somalogic competes and other industry data. Any comparison of Somalogic to the industry or to any of its competitors is based on this publicly available information and statistics and such comparis on s assume the reliability of the information available to Somalogic . Somalogic obtained this information and statistics from third - party sources, including reports by market research firms and company filin gs. While Somalogic believes such third - party information is reliable, there can be no assurance as to the accuracy or completeness of the indicated information. Neither Somalogic nor CM Life Sciences II has independently verified the information provided by the third - party sources. Trademarks This presentation may contain trademarks, service marks, trade names and copyrights of other companies, which are the propert y o f their respective owners. Solely for convenience, some of the trademarks, service marks, trade names and copyrights referred to in this presentation may be listed without the TM, SM © or ® symbols, but CM Life Scie nce s II and Somalogic will assert, to the fullest extent under applicable law, the rights of the applicable owners, if any, to these trademarks, service marks, trade names and copyrights. Private Placement The securities to which this presentation relates have not been registered under the Securities Act of 1933, as amended (the “Se curities Act”), or the securities laws of any other jurisdiction. This presentation relates to securities that CM Life Sciences II intends to offer in reliance on exemptions from the registration requirements of the Secu rit ies Act and other applicable laws. These exemptions apply to offers and sales of securities that do not involve a public offering. The securities have not been approved or recommended by any federal, state or foreign securiti es authorities, nor have any of these authorities passed upon the merits of this offering or determined that this presentation is accurate or complete. Any representation to the contrary is a criminal offense. Financial and Other Information The financial information contained in this presentation has been taken from or prepared based on the historical financial st ate ments of Somalogic for the periods presented. An audit of these financial statements is in process. Accordingly, such financial information and data may not be included in, may be adjusted in or may be presented diff ere ntly in any registration statement to be filed with the SEC by CM Life Sciences II in connection with the Transaction. Somalogic has not yet completed its closing procedures for the three months ended December 31, 2020. This presentation contains certain e stimated preliminary financial results and key operating metrics for the year ended December 31, 2020. This information is preliminary and subject to change. As such, Somalogic’s actual results may differ from the estimated preliminary results presented here and will not be finalized until Somalogic completes its year - end accounting procedures. This presentation includes certain non - GAAP financial measures (including on a forward - looking basis) such as EBITDA and EBITDA Margin. These non - GAAP measures are an addition, and not a substitute for or superior to, measures of financial performance prepared in accordance with GAAP and should not be considered as an alternative to net inc ome, operating income or any other performance measures derived in accordance with GAAP. Somalogic believes that these non - GAAP measures of financial results (including on a forward - looking basis) provide useful supplemental i nformation to investors about Somalogic . Somalogic’s management uses forward - looking non - GAAP measures to evaluate Somalogic’s projected financials and operating performance. However, there are a number of limitations related to the use of these non - GAAP measures and their nearest GAAP equivalents, including that they exclude significant expenses that are required by GAAP to be recorded in Somalogic’s financial measures. In addition, other companies may calculate non - GAAP measures differently, or may use other measures to calculate their financial performance, and therefore, Somalogic’s non - GAAP measures may not be directly comparable to similarly titled measures of other companies. Additionally, to the extent that forward - looking non - GAAP financial measures are provided, they are presented on a non - GAAP basis without reconciliat ions of such forward - looking non - GAAP measures due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliations. Use of Projections This presentation also contains certain financial forecasts, including projected revenue. Neither Somalogic’s nor CM Life Sciences II’s independent auditors have studied, reviewed, compiled or performed any procedures with respect to the projections for the purpose of their inclusion in this presentation, and accordingly, neither of them exp res sed an opinion or provided any other form of assurance with respect thereto for the purpose of this presentation. These projections are for illustrative purposes only and should not be relied upon as being necessarily indicat ive of future results. In this presentation, certain of the above - mentioned projected information has been provided for purposes of providing comparisons with historical data. The assumptions and estimates underlying the pr osp ective financial information are inherently uncertain and are subject to a wide variety of significant business, economic and competitive risks and uncertainties that could cause actual results to differ materially f rom those contained in the prospective financial information. Projections are inherently uncertain due to a number of factors outside of CM Life Sciences II’s or Somalogic’s control. While all financial projections, estimates and targets are necessarily speculative, CM Life Sciences II and Somalogic believe that the preparation of prospective financial information involves increasingly higher levels of uncertainty the further out the projection, estim ate or target extends from the date of preparation. Accordingly, there can be no assurance that the prospective results are indicative of future performance of the combined company after the Transaction or that actual results wi ll not differ materially from those presented in the prospective financial information. Inclusion of the prospective financial information in this presentation should not be regarded as a representation by any person that the res ults contained in the prospective financial information will be achieved. ® 2021 SOMALOGIC, INC. ALL RIGHTS RESERVED. PROPRIETARY AND CONFIDENTIAL.

Disclaimer Participation in Solicitation CM Life Sciences II and Somalogic and their respective directors and executive officers, under SEC rules, may be deemed to be participants in the solicitation of proxies of CM Life Sciences II’s shareholders in connection with the proposed business combination. Investors and security holders may obtain more detailed information regarding the nam es and interests in the proposed business combination of CM Life Sciences II’s directors and officers in CM Life Sciences II’s filings with the SEC, including CM Life Sciences II’s registration statement on Form S - 1, whic h was originally filed with the SEC on February 1, 2021. To the extent that holdings of CM Life Sciences II’s securities have changed from the amounts reported in CM Life Sciences II’s registration statement on Form S - 1, suc h changes have been or will be reflected on Statements of Change in Ownership on Form 4 filed with the SEC. Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of pr oxies to CM Life Sciences II’s shareholders in connection with the proposed business combination will be set forth in the proxy statement/prospectus on Form S - 4 for the proposed business combination, which is expe cted to be filed by CM Life Sciences II with the SEC. Investors and security holders of CM Life Sciences II and Somalogic are urged to read the proxy statement/prospectus and other relevant documents that will be filed with the SEC carefully and i n their entirety when they become available because they will contain important information about the proposed business combination. Investors and security holders will be able to obtain free copies of the proxy statement and other documents containing impor tan t information about CM Life Sciences II and Somalogic through the website maintained by the SEC at www.sec.gov. Copies of the documents filed with the SEC by CM Life Sciences II can be obtained free of charge by direc tin g a written request to CM Life Sciences II, Inc., 667 Madison Avenue, New York, NY 10065. ® 2021 SOMALOGIC, INC. ALL RIGHTS RESERVED. PROPRIETARY AND CONFIDENTIAL.

Overview of CM Life Sciences UNIQUE COMBINATION OF ELI CASDIN’S INVESTMENT PLATFORM AND KEITH MEISTER’S CAPITAL MARKETS AND BOARD EXPERTISE 3/27/2021 5 ® 2021 SOMALOGIC, INC. ALL RIGHTS RESERVED. PROPRIETARY AND CONFIDENTIAL. CM Life Sci en c e s I I FUNDAMENTAL Casdin Capital’s Deep Sector Expertise LONG TERM CAPITAL SECULAR GROWTH CM Life Sciences II Capital Alignment ENGAGEMENT Keith Meister’s Corporate Engagement Kevin Conroy, J.D. Chairman and Chief E x e c uti v e O ffi c er of Exact Sciences Troy Cox Former Chief Executive Officer of Foundation Medicine and Senior Vice President of U.S. BioOncology for Genentech Jason Kelly, Ph.D Co - founder and CEO of Ginkgo Bioworks S t ephe n Q uake , Ph . D Lee Otterson Professor of Bioengineering and Professor of Applied Physics at Stanford University CM LIFE SCIENCES II BOARD Technology, Biopharma, Diagnostics, and Industrial Markets

3/27/2021 6 ® 2020 SomaLogic, Inc. All rights reserved. Proprietary and confidential. An evolutionarily advanced technology platform, database and bioinformatics capability Market - validated - more than 300 customers and collaborators Proteomics knowledge leadership with launch of clinical diagnostic applications Proteomics enablement leader – 7000 proteins, moving to 10,000 Significant technology trajectory and revenue acceleration ahead &UHDWHGE\$JQL IURPWKH1RXQ3URMHFW &UHDWHGE\$GULHQ&RTXHW IURPWKH1RXQ3URMHFW &UHDWHGE\0DVVLPR,SSROLWR IURPWKH1RXQ3URMHFW

Genomics provides the code, but proteins are the primary functional and structural molecules of life. We have been able to read DNA to full genome coverage at ever decreasing cost and increasing speed. However, we have not — until SomaLogic — been able to measure a sufficient number of proteins (thousands) simultaneously to obtain a “signal” and understand it. DNA ~20KGenes Hereditary material that encodes functional biological molecules ONE AND DONE mRNA Molecule that carries DNA “directions for protein synthesis ~200K Transcripts Genomics Are The Blueprint, But Proteomics Are Dynamic Structure And Function ® 2021 SOMALOGIC, INC. ALL RIGHTS RESERVED. PROPRIETARY AND CONFIDENTIAL. STATIC Primary functional and structural molecules for all biological processes Proteins REPEAT REGULARLY >1M Proteins ~10% HUMAN PROTEOME TRANSLATED 7 3/27/2021

Leader in Enormous Untapped Proteomics Market EXPANDING PROTEOMICS AND GENOMICS MARKETS VIA UNBIASED, DEEP, AND RAPID PROTEOMICS AT SCALE 3/27/2021 8 ® 2021 SOMALOGIC, INC. ALL RIGHTS RESERVED. PROPRIETARY AND CONFIDENTIAL. DIAGNOSTIC APPLICATIONS TRANSLATIONAL RESEARCH & BIOPHARMA DEVELOPMENT BASIC RESEARCH & DISCOVERY $ 40 B $ 20 B $ 30 B ~$ 90 B Total Available Market

SomaLogic Is The Only Technology Stack Able to Resolve Comprehensive Market Need WHAT’S BEEN NEEDED 3/27/2021 9 ® 2021 SOMALOGIC, INC. ALL RIGHTS RESERVED. PROPRIETARY AND CONFIDENTIAL. WHERE MOST OF THE INDUSTRY IS TODAY S c a l ab ility Broad M ea s ure m ent Precision M ea s ure m ent P ro t eo m ic Data Co s t Small S a m p le Size Protein AI / Analytics Tools Pharma Market a cc ep t an c e Reproducible M ea s ure m ent Protein Bi o i n f or m a tic Expertise Deep M ea s ure m ent Rapid M ea s ure m ent Proteomics Co mm er c i al Revenues Geno m i c s A d v an c es (GWAS) No t A v a il ab l e P ar t i a ll y A v a il ab l e Fu ll y A v a il ab l e S c a l ab ility Broad M ea s ure m ent Precision M ea s ure m ent P ro t eo m ic Data Co s t Small S a m p le Size Protein AI / Analytics Tools Pharma Market a cc ep t an c e Reproducible M ea s ure m ent Protein Bi o i n f or m a tic Expertise Deep M ea s ure m ent Rapid M ea s ure m ent Proteomics Co mm er c i al Revenues Geno m i c s A d v an c es (GWAS) S c a l ab ility Broad M ea s ure m ent Precision M ea s ure m ent P ro t eo m ic Data Co s t Small S a m p le Size Protein AI / Analytics Tools Pharma Market a cc ep t an c e Reproducible M ea s ure m ent Protein Bi o i n f or m a tic Expertise Deep M ea s ure m ent Rapid M ea s ure m ent Proteomics Co mm er c i al Revenues Geno m i c s A d v an c es (GWAS)

Proteomics Leader: Significant First Mover Advantage 10 20 YEARS 250 PUBLICATIONS 3/27/2021 ® 2021 SOMALOGIC, INC. ALL RIGHTS RESERVED. PROPRIETARY AND CONFIDENTIAL. ESTABLISHED INDUSTRY ADOPTION | RAPIDLY GROWING REVENUE BASE & DEEP DIAGNOSTIC PIPELINE MOST SAMPLES FIRST CLINICAL TESTS IN MARKET LARGEST CUSTOMER BASE 300 + CUSTOMERS $ 550 M + 450 K SAMPLES INVESTED $ 55 M REVENUE 2020 CAGR NEXT 5 YEARS 10 x SIZE DATABASE (than nearest competitor) + 100 FIRST - IN - CLASS PROTEIN PATTERNS 20 VALIDATED CLINICAL TESTS 40 % + 250 K DEEP CLINICAL SAMPLE

• Proprietary aptamers ~700 patents issued or pending • Largest panels in the industry by 4.5x • 7,000+ plex today 10,000 in 2022 • Unparalleled sensitivity/specificity, dynamic range, reproducibility & scale • No upper limit to number that can be created (1.2 x 1,064 possible shapes) 11 ® 2021 SOMALOGIC, INC. ALL RIGHTS RESERVED. PROPRIETARY AND CONFIDENTIAL. • Largest proteomics database with deepest understanding of the proteome • 450,000+ samples growing to 1.5M+ by 2024 • 80% of samples on 5,000+ plex • 40% annotated with clinical data • Biobank contracts and unique access • Clinical partnerships expand database and fuel test development • Unmatched regulatory resource • 10+ year track record of protein data product development • Access to >1B protein measurements and 15M clinical data points • Bespoke protein bioinformatics capabilities p roteomic bioinformatics and analytics as a service (expands business model and customer access) • Artificial Intelligence and machine learning expertise PROPRIETARY | BROAD | DEEP SENSITIVE | SPECIFIC SCALE | TIME | INPUTS KNOWLEDGE AI - POWERED | APPLICATION ANALYSIS | DEVELOPMENT The Leading Proteomics Platform TECHNOLOGY &UHDWHGE\$]DP,VKDT IURPWKH1RXQ3URMHFW DATABASE &UHDWHGE\$JQL IURPWKH1RXQ3URMHFW &UHDWHGE\$GULHQ&RTXHW IURPWKH1RXQ3URMHFW AI - POWERED BIOINFORMATICS STACK 3/27/2021

SomaLogic’s Technology • Proven ability to measure >7000 proteins in a single sample from small biologic sample (30µl) • Capability to run assays simultaneously , at high throughput • Established CLIA/CAP certified lab infrastructure • Highly scalable, reproducible and market validated ADDRESSING KEY COMMERCIAL PROTEOMICS CHALLENGES B R EA D TH D EP TH SPEED CO S T SCALABILITY 3 / 12 / 21 Antibodies Nanobeads / Mass Spec. Protein Sequencing REPRODUCIBILITY LOW SAMPLE SIZE DETECTION NO PARTIAL YES ® 2021 SOMALOGIC, INC. ALL RIGHTS RESERVED. PROPRIETARY AND CONFIDENTIAL. OPPORTUNITY 12

Platform Breeds Virtuous Cycle of Value Creation 3/27/2021 13 ® 2021 SOMALOGIC, INC. ALL RIGHTS RESERVED. PROPRIETARY AND CONFIDENTIAL. TECHNOLOGY BIOINFORMATICS STACK DATABASE Data BioBank Drug Discovery Engine Clinical Trial Tools Life Sciences Research Market Companion Diagnostics BioPharma & Research Business 20 Validated Tests 10 Tests Launched Pipeline of 100+ First - in - class Tests Clinical Diagnostics Business &UHDWHGE\$]DP,VKDT IURPWKH1RXQ3URMHFW &UHDWHGE\$JQL IURPWKH1RXQ3URMHFW &UHDWHGE\$GULHQ&RTXHW IURPWKH1RXQ3URMHFW

Industry Evolution: From Enabler to Applications to Integrated Platforms 3/27/2021 14 ® 2021 SOMALOGIC, INC. ALL RIGHTS RESERVED. PROPRIETARY AND CONFIDENTIAL. EMERGING EVOLUTION OF PROTEOMIC COMPANIES FOLLOWING GENOMICS TRAJECTORY Total commercial opportunity ~$90B Proteomics TAM ~$75B current market cap ~$65B current market cap ~$10B current market cap ~$70B Genomic TAM SomaLogic has the broadest technological capability and substantial first mover advantage in proteomics to not just enable to apply to clinical diagnostics, capturing both ends of the market GENOMICS ENABLING GENOMICS APPLICATIONS PROTEOMICS ENABLERS FULL - SPECTRUM PROTEOMICS PLATFORM

An Enabler and Applications Company Traversing Enormous Market Segments

SomaLogic Research – Broad Offering Across Basic and Translational Research Market 16 WHAT WE OFFER THE LIFE SCIENCES RESEARCH MARKET SomaLogic Research BASIC RESEARCH & DISCOVERY $30B TRANSLATIONAL RESEARCH & BIOPHARMA DEVELOPMENT $20B 3/27/2021 ® 2021 SOMALOGIC, INC. ALL RIGHTS RESERVED. PROPRIETARY AND CONFIDENTIAL. COMPANION & COMPLEMENTARY DIAGNOSTICS CLINICAL TRIALS PQTL TARGETS DRUG | VACCINE TARGET ID & DEVELOPMENT NEW BIOLOGIC INSIGHTS GENOMIC & PROTEOMIC DISCOVERY

300+ Deep Industry Partnerships Built Up Over 20 Years 3/27/2021 ® 2021 SOMALOGIC, INC. ALL RIGHTS RESERVED. PROPRIETARY AND CONFIDENTIAL. 17 RECENT BUSINESS MOMENTUM AND VALIDATION Gates funded COVID19 research samples ($1M renewable grant from the $125M grant program) Other research with Gates (maternal health, child nutrition in medically developing world). July 2021 Ten - year deal to use SomaLogic’s platform for drug development Sample commitments of >60 - 70K/yr over the next several years (long - term revenue visibility) Late 2019 $24M sample deal 2020 - 2021 Desire to “co - develop” Amgen tests of interest on SomaLogic platform July 2020 INDIVIDUAL INVESTIGATORS ACADEMIC LABS PHARMA DISCOVERY CLINICAL RESEARCH ORGANIZATONS PHARMA CLINICAL TRIALS MULTI - OMICS PROVIDERS CLINICAL COMMERCIAL RISK STRATIFIERS HEALTH SYSTEMS

SomaLogic Clinical Diagnostic Market Positioning SOMASIGNAL DIAGNOSTICS APPLIED ACROSS THE CONTINUUM SomaLogic Clinical DIAGNOSTIC APPLICATIONS $40B EARLY DETECTION RISK PREDICTION PATIENT / POPULATION RISK STRATIFICATION ® 2021 SOMALOGIC, INC. ALL RIGHTS RESERVED. PROPRIETARY AND CONFIDENTIAL. DISEASE PROGRESSION TREATMENT SELECTION / COMPANION DIAGNOSTICS / RESPONSE PREDICTION 18 PROPRIETARY TEST DEVELOPMENT MULTI - OMIC PRODUCT DEVELOPMENT &UHDWHGE\$JQL IURPWKH1RXQ3URMHFW &UHDWHGE\5R\\DQ:LMD\D IURPWKH1RXQ3URMHFW

16 • What is the risk of a second cardiovascular event in 4 years if there has been a previous event ( no diagnostic test/algorithm currently exists) • ~15,000 participants have been evaluated by this test in 7 different clinical human sample studies • Performance exceeds any combination of traditional risk factors with 4 - year AUCs 0.72 - 0.84 • Calibration excellent across studies even with 5x event - rate differences (event free survival (top), event rate (bottom) • Geographically, racially and gender robust • Norway, US, Japan, multi - country… Men/Women/Black • Symptomatic, asymptomatic, heart failure +/ - , elderly without known disease • Sensitive to both increases and decreases of risk over time SomaSignal Tests SECONDARY CARDIOVASCULAR RISK EXAMPLE SomaLogic Clinical Case Study

SomaSignal NASH Panel • The world’s only non - biopsy source of all 4 components of NASH and NAFLD • 4 independent models trained against biopsy and pathology read • NAS score sensitivity from .77 to .93, and sensitive to change • Gold standard liver biopsy – clinical trials / diagnosis difficult due to risk, cost and aversion • Imaging exists, but only suggests fibrosis • Original test model - 3000 specimens from PIVENS, FLINT and large natural history studies • Further validation by the LITMUS consortium (Liver Investigation: Testing Marker Utility in Steatohepatitis) where performance was #1 out of 20 tested biomarker / biomarker combinations. FIBROSIS BIOPSY RESULT STEATOSIS BIOPSY RESULT SOMASIGNAL NASH PREDICTIONS RELATED TO BIOPSY RESULT (VALIDATION DATASET) INFLAMMATION BIOPSY RESULT BALLOONING BIOPSY RESULT SomaLogic Clinical Case Study THE “LIQUID LIVER BIOPSY” 20

Clinical Pipeline: SomaSignal Tests 21 PIPELINE AND CURRENTLY AVAILABLE TESTS 3/27/2021 ® 2021 SOMALOGIC, INC. ALL RIGHTS RESERVED. PROPRIETARY AND CONFIDENTIAL. SomaLogic Clinical LAUNCHED Q4 2019 AVAILABLE 2020 - 2023 AVAILABLE 2024+ KEY FOR TEST TYPE • Health/Wellness • Preventative Medical • Disease Management • Alcohol impact • Body fat percentage • Cardiorespiratory fitness/VO 2 max • Alcohol impact • Alzheimer’s/dementia risk • Biologic/functional age • Body fat percentage • Body weight trajectory • Bone mineral mass • Cardiorespiratory fitness/VO 2 max • Circadian cycle • Cognitive function • Cognitive trajectory • Depression/mood with aging • Diet change/hypertension correlation • Frailty • Grip strength with aging • Healthspan • Inflammatory load • Insulin sensitivity • Joint health • Lean body mass • Lifespan • Mental stress • Microbiome diversity • Physical activity • Reproductive health • Resting energy rate • Sleep quality • Smoking status • Social deprivation • Visceral fat • Cancer risk (top 15) • Coronary artery calcium surrogate • CV risk (all - comers multiple subtypes) • eGFR (kidney function) • GLP - 1 agonist response • Glucose tolerance • Functional status/ability with aging • Liver fat • Predict type II diabetes diagnosis with complications • Primary CV risk - 4 year • Secondary CV risk - 4 year SomaLogic Clinical • Cancer early detection • Cancer susceptibility (top 4) • CHF therapy sensitivity • Congestive heart failure prognosis • Congestive heart failure type • COPD risk/risk of progression • Kidney disease prognosis • NASH: 4 liver biopsy components • Pulmonary function • Rule - out symptomatic coronary heart disease • Statin adherence • Cancer susceptibility (top 4) • CHF prognosis • CHF type • Kidney disease prognosis • NASH: 4 liver biopsy components • Rule - out symptomatic coronary heart disease • Statin adherence • Coronary artery calcium surrogate • eGFR (kidney function) • GLP - 1 agonist response • Glucose tolerance • Liver fat • Predict type II diabetes diagnosis with complications • Primary CV risk - 4 year • Secondary CV risk - 4 year • Alcohol impact • Alzheimer’s/dementia risk • Biologic/functional age • Body fat percentage • Body weight trajectory • Bone mineral mass • Cardiorespiratory fitness/VO 2 max • Cognitive function • Healthspan • Insulin sensitivity • Lean body mass • Lifespan • Physical activity • Resting energy rate • Sleep quality • Smoking status • Social deprivation • Visceral fat • Lean body mass • Resting energy rate • Visceral fat • Glucose tolerance • Liver fat • Primary CV risk - 4 year • Secondary CV risk - 4 year

Fast Growing Business With Expanding High Margin Opportunity Likely upside based on this public funding round and use of capital. Will fund: • Small plex • Kits • SomaSignal test RUO use • Licensing and royalties • Data products development • Hardware and reagents (“box”) • Additional health system conversions 3/27/2021 22 ® 2021 SOMALOGIC, INC. ALL RIGHTS RESERVED. PROPRIETARY AND CONFIDENTIAL. INVESTMENT IN COMMERCIAL INFRASTRUCTURE, NEW PRODUCT AND SERVICE OFFERINGS AND HEALTH SYSTEM PARTNERSHIPS GROSS MARGIN 44% 60% 51% 53% 65% 75% OPERATING EXPENSES (m) $55 $52 $91 $99 $103 Estimated Break Even 2025 EBITDA (m) ($38) ($23) ($74) ($53) ($31) ~$250M Cumulative Cash Burn BASE CASE FINANCIALS Revenue in millions *All figures are non - GAAP and unaudited

Leading Proteomic Database Underpins Commercial Flywheel Drivers: • Lower COGS driven volume elasticity • Pharma partnerships • Population proteogenomic initiatives • Health system partnerships • Payor partnerships • Dx partnerships 3/27/2021 23 ® 2021 SOMALOGIC, INC. ALL RIGHTS RESERVED. PROPRIETARY AND CONFIDENTIAL. STRATEGIC PARTNERSHIPS AND COMMERCIAL APPLICATION TRANSLATES TO BROADER, FASTER APPLICATION DEVELOPMENT *All figures are non - GAAP and unaudited Sample Volume

Growth Acceleration

SomaLogic + CM Life Sciences: Partnership to Accelerate Growth 3/27/2021 25 ® 2021 SOMALOGIC, INC. ALL RIGHTS RESERVED. PROPRIETARY AND CONFIDENTIAL. Significant cash infusion strengthens the balance sheet, providing flexibility to aggressively pursue a comprehensive growth strategy, solidifying the competitive moat and de - risking the long - term vision FASTER DATABASE GROWTH • Deployable technology format (kits across 20+ sites in next [3 years]) • Develop product version of technology at lower cost, higher scale • 10,000+ plex and [NGS/microarrays] to expand TAM and lower COGS Multiple potential near - term partnerships and acquisitions to expand the TAM, add complementary technology formats, significantly lower COGS, validate and expand clinical applications, bolster data and bioinformatics capabilities, etc. • Increased assay capacity to create assay run time for biobank and other R&D samples • More health system relationships + creation of clinical data consortia ORGANIC & I N O R G A N IC GROWTH OPPORTUNITY ADVANCE TECH TRAJECTORY ACCELERATED DATABASE GROWTH • Acquisition of data de - identification tools • Access to more global biobanks • Pharma partnerships • Enables application development flywheel

Build, Buy, Partner: Expand Technology Stack & Distribution Channels Aggressively 3/27/2021 26 ® 2021 SOMALOGIC, INC. ALL RIGHTS RESERVED. PROPRIETARY AND CONFIDENTIAL. STRATEGY ▪ “Double down” on first mover comprehensive commercial position ▪ Combination of partnerships, investments and acquisitions ▪ Several partnerships are already initiated Added Data Services Analytics Biobank BI NextGen Platforms Protein Seq NextGen Platforms Protein Seq 10K Plex+ Expand Applications Single Cell Intracellular “Box” More Deployable Hardware Reagents Proteo - Genomics Discovery and Clinical Products Tech Trajectory NGS Alt Arrays ORGANIC Internal R&D Partnerships INORGANIC Acquisitions Partnerships Target Discovery Large scale Assay Partnerships TBD TBD TBD Licenses/ Royalties Test Development Reagents Diagnostic Partnerships

Experienced Leadership 27 Roy SMYTHE Chief Executive Officer Melody HARRIS President and COO Nebojsa JANJIC Chief Scientific Officer Alan WILLIAMS Chief Development Officer Angela BAKKER - LEE EVP Healthcare Market Tracy HERVEY EVP Research & Discovery Market Manda MORRIS Senior Director Strategic Finance Steve WILLIAMS Chief Medical Officer Jason CLEVELAND Chief Technology Officer TBD Chief Strategy Officer TBD Chief Financial Officer

Board of Directors & Financial Partners S t ephe n Q UAKE , PH . D Lee Otterson Professor of Bioengineering and Professor of Applied Physics at Stanford University Kevin CONROY, J.D . Chairman and CEO of Exact Sciences Troy COX Former CEO of Foundation Medicine and SVP of U.S. BioOncology for Genentech Jason KELLY, PH.D Co - founder and CEO of Ginkgo Bioworks 28 Blue Water Life Science Advisors Boston Millennia Partners Mossrock Capital Monashee Investment Charles M. LILLIS Co - Founder & Partner, LoneTree Capital Anne MARGULIES Vice President & Chief Information Officer, Harvard University Jessica MATHEWS Former President, Carnegie Endowment for International Peace Franck J. MOISON Former Vice Chairman, Colgate - Palmolive Eli CASDIN Chief Investment Officer and Founder, Casdin Capital Roy SMYTHE CEO, SomaLogic Former CMO for Strategy & Partnerships, Royal Philips Richard POST Former President & CEO, Autobytel, Inc.

Transaction Summary 3/27/2021 29 ® 2021 SOMALOGIC, INC. ALL RIGHTS RESERVED. PROPRIETARY AND CONFIDENTIAL. Transaction Overview Valuation / Pro Forma Ownership Sources and Uses of Funds Transaction Highlights • CM Life Sciences II (Ticker: CMIIU) is a Life Sciences focused publicly traded Special Purpose Acquisition Company (SPAC) with $276 million in cash to be deployed • CMIIU has entered into an agreement to combine with SomaLogic • PIPE size is $ 375 million • Implies a $1.2 billion post - merger enterprise value • 6 2 % SomaLogic rollover shareholders, 20 % PIPE investors, 1 4 % SPAC public investors, 4% SPAC sponsor • The Combination of SPAC trust account proceeds (assuming no redemptions) and the PIPE investment is expected to provide SomaLogic with $ 686 million of pro forma cash to enable growth on a multi - year time frame, provide liquidity for shareholders and explore additional organic and inorganic growth opportunities

SOURCES PRO FORMA VALUATION CM Life Sciences II Cash in trust $276 Share Price $10.00 PIPE Investment 375 Pro Forma Shares Outstanding 1 92.0 Selling Shareholders Equity 1,200 Equity Value $1, 920 Existing Cash on Balance Sheet 170 (+) Debt - ( - ) Pro Forma Cash 686 Total $ 2,021 Enterprise Value $1,2 3 4 USES OWNERSHIP POST - BUSINESS COMBINATION Cash to Balance Sheet $ 686 Debt Repayment 50 Equity to Selling Shareholders 1,200 Cash to Selling Shareholders 50 Estimated Transaction Costs & Expenses 3 5 Total $ 2,021 ADDITIONAL TRANSACTION DETAILS Transaction Overview 3/27/2021 30 ® 2021 SOMALOGIC, INC. ALL RIGHTS RESERVED. PROPRIETARY AND CONFIDENTIAL. SPAC Shareholders SPAC Management Shares PIPE Investors Sellers Rollover Equity • Pro forma enterprise value of $1.23bn • $ 375 mm PIPE raised at $10 per share • Transaction expected to close in Q3 of 2021 ($ in millions) 14% 4% 20% 62%

Competitor Benchmarking Disruptive Leading Platforms Proteomics Platforms Median: 24.5x 31 Source: Capital IQ as of March 26, 2021. (1): Pro forma for ~$10M in cash consideration paid for acquisition of Tetramer Shop in January 2021. (2): Pro forma for ~$517M in net proceeds from December 2020 IPO. (3): Pro forma for ~$17M in upfront cash consideration paid for the acquisition of Reference Genomics, Inc. d/b/a One Codex i n F ebruary 2021. Pro forma for net proceeds of ~$434M from January 2021 follow - on offering. (4): Pro forma for ~$378M in net proceeds from March 2021 IPO. (5): Pro forma for ~$270M in net proceeds from February 2021 follow - on offering. (6): Pro forma for ~$319M in net proceeds from December 2020 IPO and concurrent private placement and ~$98M in net proceeds f rom January 2021 follow - on offering. $1,234 $1,272 $3,512 $1,449 $1,239 $2,035 Nautilus Olink Quanterix Quantum-Si Seer EV: $1,234 $17,472 $6,143 $4,614 $2,711 $12,485 $6,454 $5,070 2022E Revenue: $85 $15 - ($ in millions) (1) (3) Enterprise Value / 2022E Revenue Enterprise Value - $122 (5) (2) (4) 3/27/2021 ® 2021 SOMALOGIC, INC. ALL RIGHTS RESERVED. PROPRIETARY AND CONFIDENTIAL. 14.6x 25.7x 26.4x 21.0x 19.9x 24.5x 9.8x 28.2x 10x Genomics AbCellera Adaptive Biotechnologies Berkeley Lights Guardant Health Invitae Twist Bioscience $17 (6) (3)

SomaLogic Is Uniquely Positioned 3/27/2021 32 ® 2021 SomaLogic, Inc. All rights reserved. Proprietary and confidential. • A proprietary platform (technology, database, bioinformatics) and a first - mover advantage • Twenty years experience, and more than 500M total investment in technology • More evolutionarily advanced position (enablement and applications) than any other proteomics company • Market validated – many customers, established products, revenue and more of each assured • The global leader in protein measurement, at 4.5X all competitors – 7,000 current, on the way to 10,000 • The world’s largest clinical proteomics database with ~500,000 samples, ~1/2 with full clinical correlation • The market leader in protein bioinformatics – 1B protein measurements and 15M clinical data points • Twenty validated first - in - class protein pattern recognition diagnostic tests, and ~100 in development • Core measurement reagent is nucleic acid, with significant technology trajectory options • A very senior management team, with experience in healthcare, data, R&D, genomics and engineering

Visit our website : www.somalogic.com Contact us: investors@somalogic.com 33

Appendix

($ in millions) Equity Total Revenue Company Market Enterprise CAGR Net Cash Value Value (TEV) CY21 CY22 CY23 '21 -'23 CY21 CY22 CY23 10x Genomics $18,063 $17,472 $496 $679 $896 34.4% 35.3x 25.7x 19.5x $591 Guardant Health 13,615 12,485 369 509 672 35.0% 33.9x 24.5x 18.6x 940 Invitae 6,775 6,454 460 661 912 40.8% 14.0x 9.8x 7.1x 321 AbCellera 6,662 6,143 576 233 147 (49.4%) 10.7x 26.4x 41.7x 602 Twist 5,623 5,070 128 180 225 32.8% 39.7x 28.2x 22.5x 553 Adaptive 5,313 4,614 150 220 321 46.2% 30.8x 21.0x 14.4x 580 Olink 3,832 3,512 — — — — — — — 320 Berkeley Lights 2,906 2,711 92 136 172 36.7% 29.4x 19.9x 15.7x 196 Seer 2,447 2,035 4 15 34 N/M N/M N/M 60.3x 539 Quanterix 1,870 1,449 95 122 158 29.2% 15.3x 11.9x 9.2x 421 Quantum Si 1,797 1,239 — 17 49 — — 72.9x 25.3x 558 Nautilus 1,659 1,272 — — — — — — — 387 Mean $5,880 $5,371 $263 $277 $359 25.7% 26.1x 26.7x 23.4x $501 Median 4,572 4,063 150 200 199 34.7% 30.1x 24.5x 19.0x 546 Revenue EV/Revenue Comparable Companies Analysis Source: Capital IQ as of March 26, 2021. Note: Revenue multiples > 100.0x and revenue CAGR > 100.0% denoted as not meaningful (“N/M”). (1): Pro forma for ~$10M in cash consideration paid for acquisition of Tetramer Shop in January 2021. (2): Pro forma for ~$17M in upfront cash consideration paid for the acquisition of Reference Genomics, Inc. d/b/a One Codex i n F ebruary 2021. Pro forma for net proceeds of ~$434M from January 2021 follow - on offering. (3): Pro forma for ~$517M in net proceeds from December 2020 IPO. (4): Pro forma for ~$378M in net proceeds from March 2021 IPO. (5): Pro forma for ~$319M in net proceeds from December 2020 IPO and concurrent private placement and ~$98M in net proceeds f rom January 2021 follow - on offering. (6): Pro forma for ~$270M in net proceeds from February 2021 follow - on offering. (1) (2) (5) (6) (3) (4)

Comparable Companies Analysis 3/27/2021 36 ® 2021 SOMALOGIC, INC. ALL RIGHTS RESERVED. PROPRIETARY AND CONFIDENTIAL. Source: Capital IQ as of March 26, 2021. Note: Revenue multiples > 100.0x and revenue CAGR > 100.0% denoted as not meaningful (“N/M”). (1): Pro forma for ~$10M in cash consideration paid for acquisition of Tetramer Shop in January 2021. (2): Pro forma for ~$17M in upfront cash consideration paid for the acquisition of Reference Genomics, Inc. d/b/a One Codex i n F ebruary 2021. Pro forma for net proceeds of ~$434M from January 2021 follow - on offering. (3): Pro forma for ~$517M in net proceeds from December 2020 IPO. (4): Pro forma for ~$378M in net proceeds from March 2021 IPO. (5): Pro forma for ~$319M in net proceeds from December 2020 IPO and concurrent private placement and ~$98M in net proceeds f rom January 2021 follow - on offering. (6): Pro forma for ~$270M in net proceeds from February 2021 follow - on offering. ($ in millions) Equity Total Revenue Company Market Enterprise CAGR Net Cash Value Value (TEV) CY21 CY22 CY23 '21 -'23 CY21 CY22 CY23 10x Genomics $18,063 $17,472 $496 $679 $896 34.4% 35.3x 25.7x 19.5x $591 Guardant Health 13,615 12,485 369 509 672 35.0% 33.9x 24.5x 18.6x 940 Invitae 6,775 6,454 460 661 912 40.8% 14.0x 9.8x 7.1x 321 AbCellera 6,662 6,143 576 233 147 (49.4%) 10.7x 26.4x 41.7x 602 Twist 5,623 5,070 128 180 225 32.8% 39.7x 28.2x 22.5x 553 Adaptive 5,313 4,614 150 220 321 46.2% 30.8x 21.0x 14.4x 580 Olink 3,832 3,512 — — — — — — — 320 Berkeley Lights 2,906 2,711 92 136 172 36.7% 29.4x 19.9x 15.7x 196 Seer 2,447 2,035 4 15 34 N/M N/M N/M 60.3x 539 Quanterix 1,870 1,449 95 122 158 29.2% 15.3x 11.9x 9.2x 421 Quantum Si 1,797 1,239 — 17 49 — — 72.9x 25.3x 558 Nautilus 1,659 1,272 — — — — — — — 387 Mean $5,880 $5,371 $263 $277 $359 25.7% 26.1x 26.7x 23.4x $501 Median 4,572 4,063 150 200 199 34.7% 30.1x 24.5x 19.0x 546 Revenue EV/Revenue (1) (2) (5) (6) (3) (4)

Health System Clinical Diagnostic Marker Progression 37 3/27/2021 ® 2021 SOMALOGIC, INC. ALL RIGHTS RESERVED. PROPRIETARY AND CONFIDENTIAL. INVESTMENT IN COMMERCIAL INFRASTRUCTURE, NEW PRODUCT AND SERVICE OFFERINGS AND HEALTH SYSTEM PARTNERSHIPS C A B D Benefits proof studies were initiated with 4 health systems. A subset of customers will become the first purchasers, and others will fast follow those, by convention. CV Risk tests, others evaluated for health econ, subgroup applications (Ex: CV risk with chemo) C A B D TBA TBA TBA TBA C A B D TBA TBA TBA TBA 2020 2021 2022 2023 HEALTH SYSTEM PARTNERSHIPS

The SomaLogic Platform 38 “SOMAMER” REAGENTS SOMASCAN ASSAY SOMALOGIC BIOINFORMATICS EXPERTISE Slow Off - Rate Modified(“SOMAmer”) Aptamers: proprietary protein - binding reagents Incorporates ~7,000 (current) unique SOMAmer reagents to measure proteins in a single sample World - Leading Biobanks Contracts and Access data Emerging Clinical Partnerships PROTEOMICS DATA PRODUCTS SOMASIGNAL TESTS SOMALOGIC PROTEOMICS DATABASE SomaSignal Research SomaSignal Clinical data 3/27/2021 ® 2021 SOMALOGIC, INC. ALL RIGHTS RESERVED. PROPRIETARY AND CONFIDENTIAL.

SomaSignal Tests 3/27/2021 • First - in - class, only diagnostic tests using protein pattern recognition • Machine learning models correlate patterns of protein expression to condition or disease from thousands measured each time • Proteins chosen for each model (16 – 360) are chosen by the machine learning model, not by the literature SOMALOGIC BIOINFORMATICS EXPERTISE World - Leading Biobanks Contracts & Access data Emerging Clinical Partnerships PROTEOMICS DATA PRODUCTS SOMASIGNAL TESTS SOMALOGIC PROTEOMICS DATABASE SomaSignal Research SomaSignal Clinical data Approach more akin to radiomics (e.g., system finds models humans cannot see) than traditional protein diagnostics Nature Medicine (2019) – test development methodology 39 ® 2021 SOMALOGIC, INC. ALL RIGHTS RESERVED. PROPRIETARY AND CONFIDENTIAL.

3/27/2021 ® 2021 SOMALOGIC, INC. ALL RIGHTS RESERVED. PROPRIETARY AND CONFIDENTIAL. 40 Evolving the SomaScan Platform NGS COGS MARGIN DEPLOYED ASSAY (“BOX”) 24 MOS The assay readout can be performed on alternative, less expensive arrays, or on NGS platforms (feasibility completed for both). Either of these approaches will significantly lower assay COGS and increase margin on all products . Within ~24 mos. either of these could be a part of a more modular deployed assay solution, adding on - premise hardware and reagents sales to current, primarily service model. PRESENT MANY OPTIONS AVAILABLE AND IN MOTION FOR TECHNOLOGY TRAJECTORY H’WARE & REAGENTS NEW ARRAY APPROACHES

3/27/2021 ® 2021 SOMALOGIC, INC. ALL RIGHTS RESERVED. PROPRIETARY AND CONFIDENTIAL. 41 • All SomaSignal tests can be run from one sample (they are algorithms derived from one data source) • Tests are repeatable and can measure change over time • Will replace more invasive, more expensive & less convenient diagnostic approaches SomaSignal Tests – First Clinical Products LEVERAGING HIGH - PLEX MEASUREMENT, PROTEIN PATTERN RECOGNITION & MACHINE LEARNING SomaLogic Clinical

Data Perpetuates Innovative Healthcare Delivery Opportunities 3/27/2021 42 ® 2021 SOMALOGIC, INC. ALL RIGHTS RESERVED. PROPRIETARY AND CONFIDENTIAL. SomaScan Variety of high - quality data inputs: clinical trials, biobanks, clinical relationships Providing the raw material for development of SomaSignal tests Creating a significant spectrum of value and benefit for life science discovery and healthcare delivery